// App-Quantinova.ai

1652 : Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study

Researchers

Presenter

  • Kenneth C. Kalunian

Principal Investigators

  • Richard A. Furie

  • Eric F. Morand

  • Ian N. Bruce

  • Susan Manzi

  • Yoshiya Tanaka

  • Kevin Winthrop

  • Gabriel Abreu

  • Ihor Hupka

  • Lijin Zhang

  • Shanti Werther

  • Micki Hultquist

  • Raj Tummala

  • Catharina Lindholm

Medical Centers

  • UC San Diego, La Jolla, CA

  • Northwell Health, Great Neck, NY

  • Deakin University, Melbourne, Australia

  • University of Manchester, Manchester, United Kingdom

  • Allegheny Health Network, Pittsburgh, PA

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Oregon Health and Science University, Portland, OR

  • AstraZeneca, Molndal, Sweden

  • AstraZeneca, Warsaw, Poland

  • AstraZeneca, Gaithersburg, MD

  • AstraZeneca, Gothenburg, Sweden

  • AstraZeneca, Bethesda, MD

Locations

  • United States

  • Australia

  • United Kingdom

  • Japan

  • Sweden

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • MDX1333

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02446912

  • NCT02446899

  • NCT02794285

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved